|
June 2017
Download the entire issue here in PDF format. Selected stories below . . .
Policy Perspectives
By Stephanie Farnia, ASBMT Director of Health Policy and Strategic Relations
 May was an extremely busy month here in the health care policy camp and, as such, I am going to try to fit several updates within the June column: IPPS Comment Period Ending Soon; Payers Misinterpreting CMS Commentary of HCT Site of Care; HRSA Revises Process for SCTOD Contract; and CMS Issues Initial Guidance for HCT Specialty Designation. Some of these issues will receive a more substantial write-up in future months – in the meantime, please contact me if you need more information on any particular item. READ MORE.
A Word from President Krishna Komanduri, MD 
I hope this finds you and your families doing well. In Miami, the lovely dry air of spring has given way to the humid breezes of summer, with spectacular but brief thunderstorms again punctuating our afternoons. This was another busy month of travel for me on behalf of the ASBMT. I had the pleasure to travel to London last month to attend the meeting of our partner, the International Society for Cellular Therapy (ISCT). One of the delights of that meeting was joining Cath Bollard (former ASBMT board member and current ISCT president) to announce the fellows selected to attend our second ASBMT-ISCT Cell Therapy Training Course (CTTC). The joy felt in London gave way to sadness later in the month, as the ASBMT lost one of its exceptional educators. Dr. H. “Jean” Khoury, a longstanding faculty member of our other signature academy, the annual Clinical Research Training Course (CRTC). READ MORE.
Value Assessment in Engineered T Cell Therapies 
On May 25 more than 95 participants gathered in Boston for ASBMT’s “Value Assessment in Engineered T Cell Therapies,” an invitation-only forum to share perspectives on value assessment frameworks that will be needed for engineered T cell therapies. Attendees reflected the diverse stakeholder groups required to determine how this novel therapy can best be integrated into available therapeutic options, including researchers, clinicians, health economists, hospital administrators, payers, and patient advocacy groups. READ MORE.
Dr. Jeffrey Chell to Retire, Dr. Randy Mills Named NMDP’s New CEO
Jeffrey W. Chell, M.D, Chief Executive Officer of the National Marrow Donor Program (NMDP) since 2000, announced last year that he would be retiring in November of 2017. On May 2, the NMDP announced that C. Randal “Randy” Mills, Ph.D. will join NMDP/Be The Match as CEO on June 30 and Dr. Chell will become CEO emeritus. READ MORE.
Also in this issue. . .
Download the entire issue here in PDF format.
|